251 related articles for article (PubMed ID: 1873592)
41. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
42. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
Ash RC; Casper JT; Chitambar CR; Hansen R; Bunin N; Truitt RL; Lawton C; Murray K; Hunter J; Baxter-Lowe LA
N Engl J Med; 1990 Feb; 322(8):485-94. PubMed ID: 2300120
[TBL] [Abstract][Full Text] [Related]
43. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
[TBL] [Abstract][Full Text] [Related]
44. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
45. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
[TBL] [Abstract][Full Text] [Related]
47. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
Copelan EA; Biggs JC; Avalos BR; Szer J; Cunningham I; Klein JP; Atkinson K; Kapoor N; Klein JL; Downs K
J Clin Oncol; 1992 Feb; 10(2):237-42. PubMed ID: 1732424
[TBL] [Abstract][Full Text] [Related]
48. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
49. Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission.
Doney K; Buckner CD; Kopecky KJ; Sanders JE; Appelbaum FR; Clift R; Sullivan K; Witherspoon R; Storb R; Thomas ED
Bone Marrow Transplant; 1987 Dec; 2(4):355-63. PubMed ID: 3332183
[TBL] [Abstract][Full Text] [Related]
50. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
Ringdén O; Labopin M; Gorin NC; Schmitz N; Schaefer UW; Prentice HG; Bergmann L; Jouet JP; Mandelli F; Blaise D; Fouillard L; Frassoni F;
Br J Haematol; 2000 Dec; 111(4):1130-7. PubMed ID: 11167752
[TBL] [Abstract][Full Text] [Related]
51. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival.
Barrett AJ; Horowitz MM; Gale RP; Biggs JC; Camitta BM; Dicke KA; Gluckman E; Good RA; Herzig RH; Lee MB
Blood; 1989 Aug; 74(2):862-71. PubMed ID: 2665858
[TBL] [Abstract][Full Text] [Related]
52. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma.
Anasetti C; Beatty PG; Storb R; Martin PJ; Mori M; Sanders JE; Thomas ED; Hansen JA
Hum Immunol; 1990 Oct; 29(2):79-91. PubMed ID: 2249952
[TBL] [Abstract][Full Text] [Related]
53. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
[TBL] [Abstract][Full Text] [Related]
54. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
[TBL] [Abstract][Full Text] [Related]
55. Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission.
Vignon M; Andreoli A; Dhédin N; Lengliné E; Masson E; Robin M; Granier C; Larghero J; Schlageter MH; de Latour RP; Socié G; Boissel N
J Adolesc Young Adult Oncol; 2017 Jun; 6(2):299-306. PubMed ID: 27983886
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
[TBL] [Abstract][Full Text] [Related]
57. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
Wagner JL; Seidel K; Boeckh M; Storb R
Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
[TBL] [Abstract][Full Text] [Related]
58. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
[TBL] [Abstract][Full Text] [Related]
59. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
[TBL] [Abstract][Full Text] [Related]
60. melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukemia: review of transplant-related mortality.
Hjiyiannakis P; Mehta J; Milan S; Powles R; Hinson J; Tait D
Leuk Lymphoma; 1997 May; 25(5-6):565-72. PubMed ID: 9250828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
